UroGen Pharma
URGN
115 hedge funds and large institutions have $641M invested in UroGen Pharma in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 55 increasing their positions, 20 reducing their positions, and 19 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 20
57% more capital invested
Capital invested by funds: $407M → $641M (+$234M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
21% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 19
13.33% more ownership
Funds ownership: 79.61% → 92.94% (+13%)
3% more funds holding
Funds holding: 112 → 115 (+3)
25% less call options, than puts
Call options by funds: $3.18M | Put options by funds: $4.24M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$28.4M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$23.5M |
| 3 |
Morgan Stanley
New York
|
+$20.6M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$18.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Superstring Capital Management
New York
|
-$4.32M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.64M |
| 3 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$2.99M |
| 4 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$2.16M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$1.28M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$243K | -16,188 | Closed |
|
|
GCP
127
GSA Capital Partners
London,
United Kingdom
| – | -$224K | -14,937 | Closed |
|
|
AIG
128
American International Group
New York
| – | -$205K | -13,664 | Closed |
|
|
SCM
129
Soleus Capital Management
Greenwich,
Connecticut
| – | -$150K | -10,000 | Closed |
|
|
MLICM
130
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$23.8K | -1,586 | Closed |
|
131
First Manhattan
New York
| – | -$22.5K | -1,500 | Closed |
|
132
Public Employees Retirement Association of Colorado
Denver,
Colorado
| – | -$21K | -1,400 | Closed |
|
|
SWS
133
SYSTM Wealth Solutions
Chicago,
Illinois
| – | -$720 | -48 | Closed |
|
|
AWM
134
Avior Wealth Management
Omaha,
Nebraska
| – | -$60 | -4 | Closed |
|
URGN Hedge Fund Activity: Q2 2024 in Review
115 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q2 2024, worth a combined $641M — up 57% from $407M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new URGN positions and 19 closed out — a net gain of 4 holders — while 55 added to existing stakes and 20 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $28.4M. The largest seller was Superstring Capital Management, exiting entirely with an estimated $4.32M sold.
- 115 institutional investors held UroGen Pharma (URGN) as of Q2 2024, up from 112 in Q1 2024.
- Funds reported $641M of UroGen Pharma stock for Q2 2024, up 57% quarter-over-quarter.
- 23 funds opened new UroGen Pharma positions in Q2 2024 and 19 closed out, a net change of +4 holders.
- The largest UroGen Pharma buyer in Q2 2024 was Adage Capital Partners, an estimated $28.4M added.
- The largest UroGen Pharma seller in Q2 2024 was Superstring Capital Management, an estimated $4.32M sold.
Based on aggregated 13F filings for Q2 2024.